of Australia has declined the approval of lecanemab (generic name) as a treatment for early Alzheimer's disease (AD) (mild cognitive impairment due to AD and mild AD dementia). Eisai remains ...

monoclonal antibody lecanemab (generic name) as a treatment for early Alzheimer's disease (AD) (mild cognitive impairment due to AD and mild AD dementia). In October 2024, the TGA made the ...

Since receiving approval from the U.S. Food and Drug Administration in 2023 as only the second Alzheimer’s-modifying drug, sales of lecanemab, marketed as Leqembi, have consistently increased ...

STOCKHOLM, Sweden, March 3, 2025 /PRNewswire/ --BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia ...